scholarly journals Role of janus kinase inhibitors in the treatment of alopecia areata

2018 ◽  
Vol Volume 12 ◽  
pp. 2323-2335 ◽  
Author(s):  
Korn Triyangkulsri ◽  
Poonkiat Suchonwanit
Keyword(s):  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors

The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review

2019 ◽  
Vol 32 (5) ◽  
Author(s):  
Ana B. Oliveira ◽  
Miguel Alpalhão ◽  
Paulo Filipe ◽  
João Maia‐Silva
Keyword(s):  
Systematic Review ◽  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors

scholarly journals Reply: Potential role of Janus kinase inhibitors in COVID-19

2020 ◽  
Vol 83 (1) ◽  
pp. e65 ◽  
Author(s):  
Maddalena Napolitano ◽  
Gabriella Fabbrocini ◽  
Cataldo Patruno
Keyword(s):  
Potential Role ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors

scholarly journals Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis

2020 ◽  
Vol Volume 9 ◽  
pp. 255-272
Author(s):  
Rhea Singh ◽  
Courtney E Heron ◽  
Rima I Ghamrawi ◽  
Lindsay C Strowd ◽  
Steven R Feldman
Keyword(s):  
Atopic Dermatitis ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors

scholarly journals Role of Janus Kinase Inhibitors in Therapy of Psoriasis

2021 ◽  
Vol 10 (19) ◽  
pp. 4307
Author(s):  
Sylwia Słuczanowska-Głąbowska ◽  
Anna Ziegler-Krawczyk ◽  
Kamila Szumilas ◽  
Andrzej Pawlik
Keyword(s):  
Side Effects ◽  
First Generation ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Jak Inhibitors ◽  
Biologic Drugs ◽  
Janus Kinases ◽  
Janus Kinase Inhibitors ◽  
Long Term Treatment

Janus kinases inhibitors are molecules that target Janus kinases—signal transducers and activators of transcription (JAK/STAT). They inhibit this intracellular signal pathway, blocking the gene transcription of crucial proinflammatory cytokines that play a central role in the pathogenesis of many inflammatory and autoimmune diseases, including psoriasis. This process reduces psoriatic inflammation. The JAK inhibitors are divided into two generations. The first generation of JAK inhibitors blocks two or more different Janus kinases. The second generation is more specified and blocks only one type of Janus kinase and has less side effects than the first generation. Tofacitinib, ruxolitinib and baricitinib belong to first generation JAK inhibitors and decernotinib and filgotinib belong to second group. This narrative review summarizes the role of Janus kinase inhibitors in the therapy of psoriasis. Oral JAK inhibitors show promise for efficacy and safety in the treatment of psoriasis. Studies to date do not indicate that JAK inhibitors are superior to recent biologic drugs in terms of efficacy. However, JAK inhibitors, due to their lack of increased incidence of side effects compared to other biologic drugs, can be included in the psoriasis treatment algorithm because they are orally taken. Nevertheless, further studies are needed to evaluate long-term treatment effects with these drugs.

scholarly journals Pulmonary arterial hypertension in interferonophaties: a case report and a review of the literature

2019 ◽  
Vol 9 (3) ◽  
pp. 204589401986983 ◽  
Author(s):  
A. Trombetta ◽  
S. Ghirardo ◽  
S. Pastore ◽  
A. Tesser ◽  
E. Piscianz ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Lupus Erythematosus ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Type I ◽  
Systemic Lupus ◽  
Janus Kinase Inhibitors ◽  
Pulmonary Arterial

Background Pulmonary arterial hypertension consists in an increase of mean pulmonary arterial pressure (PAPm ≥ 25 mmHg), and may lead to right ventricular failure. Pulmonary arterial hypertension can arise in several disorders, encompassing inflammatory conditions and connective tissue diseases. The occurrence of pulmonary arterial hypertension has recently been reported in monogenic interferonopathies and in systemic lupus erythematosus, highlighting the pathogenic role of type I interferons and paving the way to therapies aimed at inhibiting interferon signaling. Case We describe a 17-year-old boy with DNase II deficiency, presenting a clinical picture with significant overlap with systemic lupus erythematosus. During treatment with the Janus kinase inhibitor ruxolitinib, he developed pulmonary arterial hypertension, raising the question whether it could represent a sign of insufficient disease control or a drug-related adverse event. The disease even worsened after drug withdrawal, but rapidly improved after starting the drug again at higher dosage. Summary and conclusion Pulmonary arterial hypertension can complicate type I interferonopathies. We propose that ruxolitinib was beneficial in this case, but the wider role of Janus kinase inhibitors for the treatment of pulmonary arterial hypertension is not clear. For this reason, a strict cardiologic evaluation must be part of the standard care of subjects with interferonopathies, especially when Janus kinase inhibitors are prescribed.

Sign in / Sign up

Export Citation Format

Share Document